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Abstract
Background
Humoral immunity plays an important role against Pneumocystis jirovecii infection, yet clini-
cal and environmental factors that impact bronchoalveolar antibody responses to P. jirovecii
remain uncertain.
Methods
From October 2008—December 2011 we enrolled consecutive HIV-infected adults admitted
to San Francisco General Hospital (SFGH) who underwent bronchoscopy for suspected
Pneumocystis pneumonia (PCP). We used local air quality monitoring data to assign ozone,
nitrogen dioxide, and fine particulate matter exposures within 14 days prior to hospital
admission. We quantified serum and bronchoalveolar lavage fluid (BALF) antibody
responses to P. jirovecii major surface glycoprotein (Msg) recombinant constructs using
ELISA. We then fit linear regression models to determine whether PCP and ambient air pol-
lutants were associated with bronchoalveolar antibody responses to Msg.
Results
Of 81 HIV-infected patients enrolled, 47 (58%) were diagnosed with current PCP and 9
(11%) had a prior history of PCP. The median CD4+ count was 51 cells/μl (IQR 15–129)
and 44% were current smokers. Serum antibody responses to Msg were statistically signifi-
cantly predictive of BALF antibody responses, with the exception of IgG responses to
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MsgC8 and MsgC9. Prior PCP was associated with increased BALF IgA responses to Msg
and current PCP was associated with decreased IgA responses. For instance, among
patients without current PCP, those with prior PCP had a median 73.2 U (IQR 19.2–169)
IgA response to MsgC1 compared to a 5.00 U (3.52–12.6) response among those without
prior PCP. Additionally, current PCP predicted a 22.5 U (95%CI -39.2, -5.82) lower IgA
response to MsgC1. Ambient ozone within the two weeks prior to hospital admission was
associated with decreased BALF IgA responses to Msg while nitrogen dioxide was associ-
ated with increased IgA responses.
Conclusions
PCP and ambient air pollutants were associated with BALF IgA responses to P. jirovecii in
HIV-infected patients evaluated for suspected PCP.
Introduction
Pneumocystis pneumonia (PCP), a disease first clinically described in premature and malnour-
ished children in the 1940s [1] and later found to be an important opportunistic infection
among immunosuppressed patients such as those with HIV infection, continues to impart sig-
nificant morbidity and mortality worldwide [2].
Pneumocystis infection is cleared mainly through cell-mediated immunity although
humoral immune processes are also vital [3–11]. For instance, in animal studies B cell deficient
transgenic mice died from Pneumocystis infection more rapidly than B cell competent controls
[12], and in human case reports, humoral immune deficiencies such as X-linked agammaglob-
ulinemia were the sole PCP risk factors identified [13–15]. Given the clinical importance of
humoral responses to Pneumocystis and the difficulties propagating Pneumocystis in culture
[16], we have developed recombinant fragments of the Pneumocystis jirovecii major surface
glycoprotein (Msg) and enzyme-linked immunosorbent assays (ELISA) to detect antibody
responses to Msg [17–20]. Emerging research on P. jirovecii serological markers has contrib-
uted to PCP diagnostics [21, 22] and to a better understanding of the clinical [23–25] and envi-
ronmental influences [26–29] on the organism and host antibody responses.
Pneumocystis infection and pathology are usually localized to the lungs yet little is known
about the local antibody responses to P. jirovecii and what clinical and environmental factors
drive these responses [3, 30, 31]. Tobacco smoking and ambient air pollution may influence
PCP presentation and serum antibody responses to P. jirovecii [27, 28], yet it remains
unknown how inhaled pollutants impact bronchoalveolar antibody responses to Msg. In
response to these knowledge gaps we formulated the following research questions: in patients
with HIV, 1) are serum antibody responses to Pneumocystis Msg reflective of bronchoalveolar
antibody responses to Msg, 2) how do prior PCP, current PCP, and degree of immunosuppres-
sion impact bronchoalveolar antibody responses, 3) what are the influences of air pollutants
on bronchoalveolar antibody responses to Pneumocystis Msg, and 4) are bronchoalveolar
antibody responses to Pneumocystis predictive of clinically important outcomes? To address
these questions we enrolled hospitalized HIV patients undergoing bronchoscopy for suspected
PCP into a prospective cohort study, following them throughout their hospital admission and
determining serum and bronchoalveolar antibody responses to P. jirovecii Msg.
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Methods
Study population
From October 2008—December 2011, we enrolled consecutive HIV-infected adults hospital-
ized at San Francisco General Hospital (SFGH) who underwent bronchoscopy with bronch-
oalveolar lavage for suspected PCP. These patients were concurrently enrolled into the
International HIV-associated Opportunistic Pneumonias (IHOP) Study, a previously
described longitudinal cohort study of HIV-infected adults with clinical and radiographic evi-
dence of pulmonary infection [2, 32]. We included those who had PCP confirmed or ruled out
by modified Giemsa staining of bronchoalveolar lavage fluid (BALF) and who lived within the
San Francisco city limits. We excluded those lacking capacity to participate in the consent pro-
cess (from delirium, dementia, or psychiatric conditions) and those from whom we did not
have sufficient BALF for antibody testing. We followed participants throughout their stay in
the hospital and for two months following hospital discharge. We obtained clinical and demo-
graphic data through direct patient interview using standardized questionnaires and through
chart abstraction of hospital and HIV outpatient clinic paper and electronic medical records
using a standardized chart abstraction form. We then entered clinical and demographic data
into a secure Research Electronic Data Capture (REDCap, Harvard Catalyst, USA) database
using multiple validation tools to ensure accuracy.
Bronchoalveolar lavage
Bronchoalveolar lavage was performed for clinical indications following British Thoracic Soci-
ety guidelines for fiberoptic bronchoscopy in adults [33]. The bronchoscope was directed into
the most affected sub-segment(s) identified by chest imaging. Once the tip of the broncho-
scope was gently wedged into a distal airway, 20 ml of 0.9% sterile saline was instilled and
recovered by gentle aspiration. Serial 20 ml aliquots were instilled and recovered for a goal of
50% recovery of approximately 40 ml BALF. This freshly obtained BALF was placed on ice at
the bedside and immediately transported to the lab. Specimens were centrifuged and 1 ml ali-
quots of supernatant were cryopreserved at -80˚C awaiting Msg analysis.
Recombinant antigen preparation
As previously described [18, 25], using PCR with AmpliTaq enzyme (Applied Biosystems,
Carlsbad, CA, USA) we amplified 3 overlapping segments, Msg15-1119, Msg729-2282, and
Msg2015-3332, of the entire Msg gene derived from P. jirovecii infected human lung. We inserted
these segments into pET30 E. coli expression systems (Novagen, Madison, WI, USA) to gener-
ate corresponding Msg proteins: MsgA (amino-terminus), MsgB (middle portion), and
MsgC1 (carboxyl terminus). As the Msg carboxyl-terminus has been found to be the most
antigenically conserved region of the Msg protein [17], we created three additional recombi-
nant proteins from this region: MsgC3, MsgC8, and MsgC9 [20]. Proteins were purified by
affinity chromatography.
Measurement of antibody responses to Msg
We used previously developed ELISA protocols to quantify IgM and IgG serologic responses
to the aforementioned recombinant Msg constructs [24]. Similarly, to determine IgA, IgM,
and IgG responses to Msg in BALF, we tested BALF and standard reference specimens against
each Msg construct, using phosphate-buffered saline (PBS) without Msg as the negative con-
trol, correcting the reactivity of each BALF specimen to Msg by subtracting the mean optical
density with PBS alone from the mean optical density with Msg [34]. As previously described,
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we generated a standard curve for each Msg construct on each day that the assay was per-
formed, and used this curve to calculate units of reactivity [25]. We diluted BALF samples at
1:5 to 1:10 to fit the linear portion of the standard curves. Taking into account the dilution, we
then calculated units of reactivity. Of note, at the time of this analysis, IgA protocols had only
been developed for BALF to MsgA, MsgC1, and MsgC8, but not against the other Msg con-
structs, and not for serum. For this study, BALF was diluted 1:5, and serum 1:100 prior to anal-
ysis. Antibody responses reported in the results and tables were not corrected for the dilution
factor.
Ambient air pollutant measurements
We determined daily mean concentrations of particulate matter< 2.5 μm in diameter (PM2.5)
(μg/m3), daily maximum 1-hour nitrogen dioxide (NO2) concentrations in parts per billion
(ppb), and daily maximum 8-hour ozone (O3) concentrations (ppb) at the single, centrally
located monitoring station in San Francisco on 10 Arkansas Street operated by the Bay Area
Air Quality Management District in compliance with U.S. Environmental Protection Agency
regulations. Ambient air pollutant exposures were assigned for each of the 14 days prior to
each participant’s hospital admission for suspected PCP. We chose this time frame a priori
given that this is the typical subacute time course from subclinical to fully symptomatic PCP in
which lung antibody responses to P. jirovecii infection are mounting [2, 7, 35, 36].
Ethical considerations
The study was approved by the institutional review boards at the University of California, San
Francisco and the University of Cincinnati. Written informed consent was obtained from each
participant.
Statistical analyses
For descriptive statistics of baseline characteristics Student’s t-test was used for continuous
variables and Chi-squared and Fisher’s exact testing for categorical variables. To test the corre-
lation between serum and BALF antibody responses, the Pearson correlation coefficient r was
used and those with undetectable antibody responses were excluded from the analysis. Poten-
tial confounders were selected a priori based on their biologically plausible association with
both predictors and outcomes and included age, sex, race, ethnicity, CD4 cell count, HIV RNA
viral load, receipt of antiretroviral therapy or Pneumocystis prophylaxis at the time of admis-
sion, a prior history of PCP, current tobacco smoking (within the two months prior to admis-
sion), and homelessness. Potential confounders that were associated with outcome at a level
of statistical significance of P< 0.2 in bivariate analyses were included in final multivariable
regression analyses. We tested the association between serum and BALF antibody responses to
each Msg construct using multivariable linear regression analyses excluding those with unde-
tectable antibody responses. We tested the association of BALF IgA responses to Msg with a
current diagnosis of PCP using multivariable Tobit regression analyses specified for left cen-
sored data, stratifying by prior PCP history. We tested for effect modification by defining
interaction terms between prior PCP and IgA responses to each of the following Msg: MsgA,
MsgC1, and MsgC8, fitting separate multivariable Tobit regression models with each interac-
tion term and reporting effect modification for a P interaction 0.05. Similarly, separate mul-
tivariable Tobit regression analyses were used to test the associations between each pollutant
(scaled to 10 μg/m3 PM2.5, 10 ppb of NO2, and 10 ppb of O3) on each of the 14 days prior to
admission and BALF IgA responses to Msg. Results were reported as β coefficients represent-
ing the change in BALF IgA (U) predicted by a 10 unit increase in pollutant, along with 95%
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CIs and P values. To test the influence of ambient air pollutants and antibody responses on
clinical outcomes multivariable linear regression models were fitted with the predictors (ambi-
ent air pollutant levels and BALF IgA responses to Msg constructs) and the outcome (length of
hospital admission). Multivariable Cox models were fitted to test associations of the same pre-
dictors with 2-month mortality.
Results
Baseline characteristics
We enrolled 297 HIV-infected patients with suspected pulmonary infection into the IHOP
prospective cohort study between October 2008 and December 2011 (Fig 1). From this cohort,
bronchoscopy with bronchoalveolar lavage was performed in 91 patients with suspected
PCP. Ten of these patients were excluded because the quantity of BALF, after use for clinical
diagnostics, was insufficient for Msg analysis. The remaining 81 patients, all San Francisco
Fig 1. Enrollment flow chart. Abbreviations: IHOP, International HIV-associated Opportunistic Pneumonias Study; BAL,
bronchoalveolar lavage; PCP, Pneumocystis pneumonia; Msg, recombinant Pneumocystis jirovecii major surface
glycoprotein.
https://doi.org/10.1371/journal.pone.0180212.g001
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residents, were included in the final analysis: 47 with laboratory-confirmed PCP and 34 with-
out PCP. Additional pulmonary infections diagnosed included bacterial or viral community
acquired pneumonia (n = 36, 44%); health care associated, hospital acquired, or ventilator
associated pneumonia (n = 4, 4.9%); pulmonary Mycobacterium avium complex (MAC) infec-
tion (n = 3, 3.7%); non-PCP fungal pneumonia (n = 2, 2.5%), and active pulmonary tuberculo-
sis (n = 1, 1.2%). Multiple pulmonary infections were present in 15 patients with PCP (32%)
and two patients without PCP (5.9%). Noninfectious causes of respiratory symptoms included
Kaposi’s sarcoma (n = 5, 6.2%); asthma and/or chronic obstructive pulmonary disease
(COPD) (n = 3, 3.7%); pulmonary emboli (n = 1, 1.2%); and pulmonary edema (n = 1, 1.2%).
Participants were predominantly middle-aged (median 46 years, IQR 39–50), male (89%),
and white (48%) (Table 1). Nearly half of patients were current tobacco smokers, and 19%
were homeless. Among patients with PCP, CD4 counts were lower (median 45 vs. 72 cells/μl),
and viral loads were higher (5.25 vs. 4.35 log10 copies/ml) when compared to patients without
PCP (these difference did not reach statistical significance P = 0.07 and 0.13, respectively).
Patients without PCP compared to patients with PCP were statistically significantly more
likely to be taking antiretroviral therapy (74% vs 11%, P< 0.001) and PCP prophylaxis (31%
vs. 6.4%, P = 0.003).
Ambient air pollutant exposures
Over the 14 days prior to hospitalization maximum 8-hr O3 levels ranged from 19–55 ppb
(median 38, IQR 34–43); maximum 1-hr NO2 levels ranged from 20–93 ppb (median 49, IQR
Table 1. Baseline characteristics by PCP diagnosis, n = 81.
Characteristic Total PCP-n (%)* PCP+n (%) P value
N 81 34 47
Age, median (IQR), years 46 (39–50) 46 (42–54) 45 (38–50) 0.16
Male 72 (89) 30 (88) 42 (89) 0.87
Race/Ethnicity 0.77
White 39 (48) 14 (41) 25 (53)
Black 21 (26) 11 (32) 10 (21)
Hispanic 13 (16) 5 (15) 8 (17)
Asian 6 (7.4) 3 (8.8) 3 (6.4)
Native American 2 (2.5) 1 (2.9) 1 (2.1)
CD4 count, median (IQR), cells/μl 51 (15–129) 72 (14–220) 45 (16–100) 0.07
Viral load (log10 copies/ml) 5.10 (4.31–5.50) 4.35 (1.87–5.28) 5.25 (4.86–5.70) 0.13
Antiretroviral therapy† 28/76 (37) 23/31 (74) 5/45 (11) <0.001
PCP prophylaxis† 13/79 (16) 10/32 (31) 3/47 (6.4) 0.003
Prior PCP 9 (11) 4 (12) 5 (11) 0.87
Current tobacco smoker 34/77 (44) 15/32 (47) 19/45 (42) 0.69
Homeless 15 (19) 7 (21) 8 (17) 0.68
Ozone, 8-hr maximum‡ median (IQR), ppb 38 (34–43) 38 (34–43) 39 (35–45) 0.20
NO2, 1-hr maximum, median (IQR), ppb 49 (41–58) 52 (41–59) 49 (40–58) 0.70
PM2.5, 24-hr maximum, median (IQR), μg/m3 19.2 (15.7–23.0) 20.7 (16.4–24.0) 18.7 (14.9–22.7) 0.52
Abbreviations: PCP, Pneumocystis pneumonia; NO2, nitrogen dioxide; PM2.5, particulate matter < 2.5 μm in diameter
*Columns represent n (%) unless otherwise indicated
†Self-reported adherence to therapy at the time of enrollment
‡Maximum 8-hour concentration over the 14 days preceding hospitalization
https://doi.org/10.1371/journal.pone.0180212.t001
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41–58); and maximum 24-hr PM2.5 levels ranged from 6.1–49.8 μg/m3 (median 19.2, IQR
15.7–23.0) (Table 1). Air pollutant levels were similar for those with PCP compared to those
without PCP.
Serum and BALF antibody responses to Pneumocystis
The majority of patients exhibited detectable BALF IgA responses to Msg: 52% had detectable
responses to MsgA, 90% to MsgC1, and 89% to MsgC8 (Table 2). However, only 8.6–26% of
patients had detectable BALF IgM responses to Msg, and only 10–48% of patients had detect-
able BALF IgG responses to Msg. Serum and BALF antibody responses to Msg were positively
correlated (r = 0.30–0.86 for IgM and 0.13–0.56 for IgG) with the strongest correlations seen
for MsgA, MsgB, and MsgC1. Serum IgM and IgG antibody responses to Msg were highly pre-
dictive of BALF antibody responses to Msg in multivariable analyses, with the exception of
IgG responses to MsgC8 and MsgC9.
Immune characteristics and BALF IgA responses to Pneumocystis
We evaluated mean IgA responses to Msg constructs by CD4 count, viral load, antivirals, and
PCP prophylaxis, finding that taking antiretrovirals and/or PCP prophylaxis was associated
with statistically significantly higher mean IgA responses to Msg (S1 Table).
Table 2. Serum and BALF antibody responses to Msg.
Antibody Msg construct Subjects with
detectable antibody, n
(%)
Mean (SD) antibody level,
Units*
Correlation and linear regression analyses comparing
serum to BALF antibody responses for each Msg
construct§§
BALF Serum BALF Serum Correlation† r Effect estimate β‡§ (95%CI) P value
n = 81 n = 78** n = 81 n = 78**
IgA MsgA 42 (52) - 9.8 (25) - - - -
MsgC1 73 (90) - 16 (36) - - - -
MsgC8 72 (89) - 25 (39) - - - -
IgM MsgA 18 (22) 74 (95) 8.5 (37) 60 (100) 0.86 0.32 (0.28, 0.37) <0.001
MsgB 13 (16) 75 (96) 2.7 (17) 32 (64) 0.67 0.18 (0.13, 0.23) <0.001
MsgC1 12 (15) 76 (97) 2.2 (11) 30 (28) 0.35 0.14 (0.06, 0.23) 0.002
MsgC3 10 (12) 51 (65) 0.96 (4.1) 6.0 (8.9) 0.35 0.18 (0.08, 0.29) 0.001
MsgC8 7 (8.6) 69 (88) 1.2 (6.1) 12 (15) 0.35 0.14 (0.06, 0.23) 0.002
MsgC9 21 (26) 74 (95) 3.7 (16) 23 (23) 0.30 0.23 (0.07, 0.39) 0.006
IgG MsgA 39 (48) 72 (92) 25 (54) 118 (112) 0.53 0.30 (0.20, 0.40) <0.001
MsgB 8 (10) 38 (49) 2.2 (8.5) 14 (24) 0.54 0.19 (0.13, 0.26) <0.001
MsgC1 14 (17) 70 (90) 11 (26) 54 (48) 0.56 0.24 (0.13, 0.34) <0.001
MsgC3 22 (27) 71 (91) 25 (57) 189 (203) 0.29 0.08 (0.02, 0.15) 0.02
MsgC8 21 (26) 60 (77) 13 (30) 46 (67) 0.13 0.07 (-0.04, 0.19) 0.19
MsgC9 24 (30) 59 (76) 29 (64) 85 (80) 0.21 0.14 (-0.03, 0.32) 0.11
Abbreviations: Msg, recombinant Pneumocystis jirovecii major surface glycoprotein; BALF, bronchoalveolar lavage fluid.
*BALF was diluted 1:5, and serum 1:100 prior to analysis. Values reported are uncorrected for the dilution factor
†Pearson correlation r between serum and BALF antibody response to each Msg construct
‡The change of BALF antibody responses to Msg (Units) predicted by a 1 Unit increase in serum antibody responses to Msg
§Multivariable linear regression adjusted for potential confounders—age, gender, race, CD4 count, viral load, antiretroviral therapy, PCP prophylaxis, prior
PCP, current tobacco smoking, and homelessness—that were significant at a level of P < 0.2 in bivariate analyses.
**Missing serum specimens for 3 participants
§§Patients without detectable antibody responses were excluded from the analyses
https://doi.org/10.1371/journal.pone.0180212.t002
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Association of prior and current PCP with BALF IgA responses to
Pneumocystis
Both a current diagnosis of PCP and a prior history of PCP were associated with BALF IgA
responses to Msg. When stratifying by a current diagnosis of PCP, IgA responses to Msg were
generally higher in those with a prior history of PCP compared to those with no prior history
of PCP (Table 3). For instance, among patients without current PCP, those with a prior PCP
history had a median IgA response to MsgC1 of 73.2 U (IQR 19.2–169) compared to 5.00 U
(3.52–12.6) in those without prior PCP. Similar findings were evident for IgA responses to
MsgA and MsgC8, but were statistically significant only for MsgC1 (P = 0.007).
Additionally, a current diagnosis of PCP was associated with decreased BALF IgA responses
to Msg in linear regression analyses (Table 4). Again, these findings were most significant for
IgA responses to MsgC1. For instance, in unadjusted analysis, a current diagnosis of PCP was
associated with a 22.5 U lower BALF IgA response to MsgC1 compared to those individuals
without current PCP; β -22.5, 95% CI -39.2, -5.82, P = 0.009). Findings were consistent in
adjusted regression analyses, but with reduced statistical significance. Stratifying by prior PCP,
the effect of current PCP on IgA responses to MsgC1 was greater (more negative) in those
with a prior history of PCP compared to those without prior PCP (β -85.0 vs. -13.7, P interac-
tion = 0.003). However, statistically significant effect modification was not seen for IgA
responses to MsgA or MsgC8.
Association of air pollutant exposures with BALF IgA responses to
Pneumocystis
Ambient air pollutant exposures in the 14 days prior to hospital admission were associated
with BALF IgA responses to Msg. Increased daily 8-hr maximum O3 exposures were
Table 3. BALF IgA responses to Msg by current and prior PCP.
Msg construct IgA Response, median (IQR), Units
Total No current PCP Current PCP
No prior PCP Prior PCP Total No prior PCP Prior PCP Total
n = 81 n = 30 n = 4 n = 34 n = 42 n = 5 n = 47
MsgA 1.05 (0–5.29) 1.12 (0–14.5) 15.7 (5.30–33.1) 1.40 (0–17.3) 0.53 (0–3.09) 0 (0–3.75) 0 (0–3.75)
MsgC1 5.32 (3.52–11.2) 5.00 (3.52–12.6) 73.2 (19.2–169) 5.26 (3.82–25.2) 5.32 (2.37–8.63) 6.69 (4.12–7.86) 5.34 (2.37–8.63)
MsgC8 13.3 (4.93–25.4) 11.9 (4.87–41.4) 22.5 (18.5–27.4) 13.8 (5.81–31.8) 12.0 (2.84–19.3) 31.5 (8.43–44.5) 12.8 (4.25–22.6)
Abbreviations: PCP, Pneumocystis pneumonia; Msg, recombinant Pneumocystis jirovecii major surface glycoprotein
https://doi.org/10.1371/journal.pone.0180212.t003
Table 4. Effect of current PCP on BALF IgA responses to Msg, stratified by a prior history of PCP.
Msg construct Regression β coefficient* (95%CI), Units
All patients, unadjusted All patients, adjusted† No prior PCP Prior PCP P interaction
MsgA -18.4 (-36.9, 0.21) -7.88 (-26.6, 10.9) -16.4 (-37.3, 4.44) -25.2 (-53.4, 3.06) 0.53
MsgC1 -22.5 (-39.2, -5.82) -17.3 (-37.3, 2.67) -13.7 (-27.3, -0.15) -85.0 (-171, 1.16) 0.003
MsgC8 -9.64 (-28.5, 9.24) -2.45 (-22.9, 18.0) -11.4 (-32.7, 9.95) 5.28 (-16.9, 27.5) 0.57
Abbreviations: PCP, Pneumocystis pneumonia; Msg, recombinant Pneumocystis jirovecii major surface glycoprotein
*The change in antibody response to Msg (Units) predicted by a current diagnosis of PCP
†Multivariable linear regression adjusted for potential confounders—age, gender, race, CD4 count, viral load, antiretroviral therapy, PCP prophylaxis, prior
PCP, current tobacco smoker, and homeless—that were significant at P < 0.2 in bivariate analyses.
https://doi.org/10.1371/journal.pone.0180212.t004
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associated with suppressed IgA responses to Msg (Fig 2a and S1a Fig). Findings were most sig-
nificant for exposures two weeks prior to admission. For instance, each 10 ppb increase in
daily 8-hr maximum O3 was associated with an 11.1 U reduction in IgA responses to MsgA
(β -11.1, 95% CI -22.0, -0.23, P = 0.046), an 11.2 U reduction in IgA responses to MsgC1 (β
-11.2, 95% CI -20.0, -2.4, P = 0.01), and a 20.6 U reduction in IgA responses to MsgC8 (β -20.6,
95% CI -31.7, -9.50, P< 0.001) at 14 days prior to admission. Conversely, NO2 exposures were
associated with increased IgA responses to Msg, most statistically significant for IgA responses
to MsgC1 at one week prior to hospital admission and IgA responses to MsgC8 at 2 days prior
to hospital admission (Fig 2b and S1b Fig). For instance, each 10 ppb increase in daily 1-hr
maximum NO2 was associated with an 11.4 U increase in IgA response to MsgC8 two days
prior to patients’ admission (β 11.4, 95% CI 5.17, 17.6, P< 0.001). Current tobacco smoking,
however, was not associated with statistically significant increases or decreases in BALF IgA
responses.
Association of air pollutant exposures and IgA responses with clinical
outcomes
Neither maximum levels of NO2, O3, and PM2.5 nor current tobacco smoking were statistically
significantly associated with length of hospital admission or 2-month mortality. Similarly,
BALF IgA responses to the Msg constructs were not statistically significantly associated with
these clinical outcomes (see Supporting Information, S1 Data Set).
Discussion
In this prospective cohort study we investigated clinical and environmental influences on
bronchoalveolar antibody responses to P. jirovecii Msg constructs. We found that serum anti-
body responses to Msg were predictive of bronchoalveolar responses, and that although most
patients had BALF IgA responses to Msg, the majority did not have detectable BALF IgM or
IgG responses. PCP was significantly associated with BALF IgA responses to Msg such that
those with a prior history of PCP (and not current PCP) had elevated IgA responses and those
with a current diagnosis of PCP had reduced IgA responses. Pre-admission ambient levels of
O3 were associated with decreased IgA responses while NO2 was associated with increased
BALF IgA responses to Msg.
There was a moderate correlation between BAL and serum antibody responses and a highly
statistically significant association between BAL and serum antibody responses using multivar-
iable linear regression analysis. The correlation and level of significance could be strong
enough to be clinically relevant. Our study is hypothesis generating, and more studies are
needed to evaluate the clinical utility of antibody responses to Pneumocystis not only in serum
but also in BALF.
Those with a prior history of PCP had higher IgA responses to Pneumocystis Msg. This sug-
gests immunologic memory to prior Pneumocystis infection. Furthermore, IgA responses were
present even in those without prior or current PCP, suggesting immunologic memory to prior
subclinical P. jirovecii infection or colonization, or perhaps IgA responses to current subclini-
cal infection or colonization. Prior studies have found that up to 85% of humans are colonized
with P. jirovecii during early childhood with many converting during mild respiratory illnesses
thought to be Pneumocystis infections [37, 38]. In another study of hospitalized HIV-infected
patients with non-Pneumocystis pneumonia, 68% were colonized with P. jirovecii [39].
Those with current PCP experienced lower BALF antibody responses to Msg compared to
those without a current diagnosis of PCP, similar to previously reported findings [30]. The
mechanisms for lower IgA responses to Msg in HIV-infected patients with PCP are unclear.
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Fig 2. Bronchoalveolar IgA responses to MsgA, MsgC1, and MsgC8 predicted by a 10 ppb increase in (a) daily
8-hr maximum ozone and (b) daily 1-hr maximum nitrogen dioxide on each of the 14 days prior to hospital
admission. Each point indicates a regression β coefficient estimating the IgA response to Msg for every 10 ppb increase in
pollutant. Asterisked points represent statistically significant (P < 0.05) regression β coefficients. Multivariable Tobit
regression analyses adjusted for potential confounders—age, gender, race, CD4 count, viral load, antiretroviral therapy,
PCP prophylaxis, prior PCP, current tobacco smoker, and homelessness—that were significant at a level of P < 0.2 in
bivariate analyses were used to calculate regression β coefficients. Abbreviations: PCP, Pneumocystis pneumonia; Msg,
recombinant Pneumocystis jirovecii major surface glycoprotein.
https://doi.org/10.1371/journal.pone.0180212.g002
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IgA is a first-line humoral defense against airway pathogens and it is conceivable that low IgA
responses were a predisposing factor for PCP development. Secretory IgA binds to airspace
pathogens to facilitate clearance. Thus, it is also possible that binding of IgA to the high burden
of P. jirovecii in the airways and alveoli of patients with current PCP outstripped IgA produc-
tion. Detectable IgA responses to Msg were present in the majority of patients whereas IgM
and IgG responses to Msg were less common. This likely reflects the larger size of IgM and
IgG with the resultant difficult passage into airways except by means of transudation of blood
fluids into inflamed airways.
Immune status plays an important role in antibody responses to Pneumocystis. In a large
prospective cohort study of hospitalized patients with suspected pulmonary infection in
Kampala, Uganda, we found statistically significantly lower serum IgM responses to MsgC1,
MsgC3, MsgC8, and MsgC9 in patients infected with HIV compared to those not infected,
and among those with HIV, CD4 <200 also predicted lower IgM responses [25]. In the cur-
rent study in San Francisco, we found that, in unadjusted analyses, antiretroviral use was
associated with increased IgA responses to Msg, possibly through an immune reconstitution,
though we did not find CD4 or viral load to be statistically significantly associated with IgA
responses. Similarly, PCP prophylaxis was associated with higher IgA responses to Msg, per-
haps through prevention of PCP organisms in the airway that would lead to consumption of
secretory IgA.
This is the first published study to our knowledge to examine the impact of air pollutants
on bronchoalveolar antibody responses to Pneumocystis. Ambient O3 levels in the 2 weeks
prior to admission for respiratory illness were associated with a trend towards decreased
BALF IgA responses to Msg, while NO2 levels were associated with a trend towards increased
responses. It is unclear why the two pollutants were associated with antibody responses in
opposite directions. One possible explanation is that air pollutants can have both inflamma-
tory and suppressive effects on the immune system as evidenced in numerous studies. O3 is
a potent oxidant resulting in bronchoalveolar [40, 41] and systemic [42, 43] inflammation.
Nevertheless, consistent with our findings, animal studies have found that rats in the first 2
weeks of exposure to O3 experienced decreased antibody responses to microbial antigen
such as Listeria antigen [44]. NO2 is also pro-inflammatory but animal and human exposure
studies have found mixed effects of NO2 inhalation on bronchoalveolar and systemic anti-
body responses [45–49]. A recent study of ours found increased ambient levels of NO2 to
be associated with suppressed serum IgM responses to Pneumocystis Msg, whereas IgG
responses were not suppressed [28]. Tobacco smoke, which contains NO2 along with numer-
ous other toxic compounds [50], has been found to be associated with decreased serum IgG
responses to Pneumocystis Msg in a prior study [51]. Our study is the first to evaluate the
association of smoking with BALF antibody responses to Msg, and no statistically significant
associations were evident. However, cotinine levels were not available to verify and quantify
tobacco smoke exposure. Although the trends of air pollutant associations with BALF IgA
levels observed in this small prospective cohort study are intriguing, with the small sample
size and high P values the findings remain inconclusive and further studies are needed in
this area. San Francisco air pollutant levels are relatively low compared to other large urban
areas [52] and it is possible that more pronounced effects would be seen in more heavily pol-
luted areas.
Finally, neither air pollutant levels prior to admission nor BALF IgA responses to Pneumo-
cystis Msg were associated with adverse clinical outcomes as measured by prolonged length of
hospital admission and mortality. However, our small sample size with few deaths make it dif-
ficult to interpret these findings.
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Conclusions
Prior studies have shown that humoral immunity plays an important role in host defense
against P. jirovecii. In our study we found that both clinical and environmental factors were
associated with BALF IgA responses to Pneumocystis Msg. IgA was increased in those with a
prior history of PCP yet decreased in those with current PCP, findings suggestive of immuno-
logic memory and possible airway consumption during active infection, though small num-
bers in these subgroups limit the generalizability of these findings. Ozone levels within the two
weeks prior to hospital admission were associated with decreasing trends of IgA responses to
Msg, while NO2 levels were associated with increasing trends of IgA to Msg. Although air pol-
lutant and BALF IgA responses to Msg were not associated with clinical outcomes in this pro-
spective cohort, the sample size was small and air pollutant levels low, and further studies are
needed to evaluate the clinical significance of environmental influences on lung immunity
against P. jirovecii.
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